Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine

Four large trials have recently evaluated the effects of anti-inflammatory drugs in the secondary prevention of major cardiovascular events (MACE) in over 25 000 patients followed for 1.9–3.7 years. CANTOS tested subcutaneous canakinumab [an anti-interleukin (IL) 1β antibody] 300 mg every 3 months a...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreotti, Felicita, Maggioni, Aldo Pietro, Campeggi, Alice, Iervolino, Adelaide, Scambia, Giovanni, Massetti, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503530/
https://www.ncbi.nlm.nih.gov/pubmed/34650351
http://dx.doi.org/10.1093/eurheartj/suab084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503530/
https://www.ncbi.nlm.nih.gov/pubmed/34650351
http://dx.doi.org/10.1093/eurheartj/suab084

Ejemplares similares